Abstract

Coronavirus disease 2019 (COVID-19) is characterized by a pro-inflammatory state associated with organ failure, thrombosis, and death. We investigated a novel inflammatory biomarker, γ fibrinogen (GPF), in 103 hospitalized patients with COVID-19 and 19 healthy controls. We found significant associations between GPF levels and the severity of COVID-19 as judged by blood oxygen saturation (SpO₂). The mean level of GPF in the patients with COVID-19 was significantly higher than in controls (69.8 (95% CI 64.8–74.8) mg/dL compared with 36.9 (95% CI 31.4–42.4) mg/dL, p < 0.0001), whereas C-reactive protein (CRP), lactate dehydrogenase (LDH), and total fibrinogen levels were not significantly different between groups. Mean GPF levels were significantly highest in patients with severe COVID-19 (SpO₂ ≤ 93%, GPF 75.2 (95% CI 68.7–81.8) mg/dL), compared to mild/moderate COVID-19 (SpO₂ > 93%, GPF 62.5 (95% CI 55.0–70.0) mg/dL, p = 0.01, AUC of 0.68, 95% CI 0.57–0.78; Youden’s index cutpoint 62.9 mg/dL, sensitivity 0.64, specificity 0.63). In contrast, CRP, interleukin-6, ferritin, LDH, D-dimers, and total fibrinogen had weaker associations with COVID-19 disease severity (all ROC curves with lower AUCs). Thus, GPF may be a useful inflammatory marker of COVID-19 respiratory disease severity.

Introduction

Coronavirus disease 2019 (COVID-19) is a viral respiratory disease that results in high levels of pro-inflammatory and pro-thrombotic biomarkers that are associated with worse outcomes, including death. Elevated levels of C-reactive protein (CRP), interleukin-6 (IL-6), ferritin, lactate dehydrogenase (LDH), D-dimer, and fibrinogen have suggested various potential mechanisms in the pathogenesis of poor outcomes in COVID-19. For example, elevated levels of CRP, ferritin, and fibrinogen indicate activation of the acute phase response, while elevated circulating D-dimer levels suggest that fibrinolytic pathways are likely intact and dissolving fibrin. Despite this, fibrin deposits in lungs and other organs suggest dysregulation of balance in fibrin-forming (i.e., thrombin generation) and dissolving (i.e., plasmin generation) pathways, and autopsies of patients with COVID-19 show the presence of thrombosis in up to 60% of the patients.

γ fibrinogen (GPF) is a novel inflammatory biomarker that has been associated with cardiovascular and inflammatory diseases. We have previously shown that extraordinarily high levels of GPF in a small population of patients with COVID-19 were associated with the need for extracorporeal membrane oxygenation and death. We therefore tested the hypothesis that GPF levels can stratify COVID-19 respiratory disease severity in a larger population of patients.

Patients And Methods

Study Participants
This study was approved by the Institutional Ethical Committee at the Micro Therapeutics Laboratory, Chennai, India and Saveetha Medical College, Chennai, India. All participants provided written informed consent.

Patients with COVID-19

Patients were recruited from Saveetha Hospital. Inclusion criteria were hospitalized patients aged 18–65 years and laboratory confirmation of infection with SARS-CoV-2 by positive reverse transcription polymerase chain reaction (RT-PCR). Exclusion criteria were pregnant or lactating women, participation in any interventional drug clinical study during the study, or a known inflammatory condition. Patients were enrolled between June 14, 2021 and February 21, 2022. Blood samples were obtained and clinical characteristics were determined at admission.

Healthy controls

Inclusion criteria were healthy volunteers age 18–65 years with laboratory confirmation of non-infection with SARS-CoV-2 by negative RT-PCR. Exclusion criteria were known bleeding disorders, liver or kidney disease, cancer, history of surgery or thrombotic event within the past 3 months, previous history of viral infection and other diseases, or participation in any other study.

Laboratory Testing

Subjects had 2 ml of whole blood collected in 3.2% sodium citrate at admission, which was processed into plasma and banked at -80°C. Ferritin, D-dimer, and IL-6 were measured using chemiluminescence (Maglumi), CRP using turbidimetrics (Turbilatex), LDH using a latex reagent (Mindray), and total fibrinogen using a clot-based auto chemistry analyzer (Beacon Diagnostics PVT LTD). Cycle threshold (Ct) values for (RT-PCR) were obtained from the Micro Therapeutics Laboratory and Saveetha Medical College. GPF was analyzed using a commercial enzyme-linked immunoassay (Gamma Coeur ELISA Kit - GCEK001, Zeus Scientific).

Statistical Analysis

Severity of COVID-19 was defined as mild/moderate (SpO₂ > 93%) or severe (SpO₂ ≤ 93%) on room air measured at admission. Differences in GPF levels among patients with mild/moderate or severe COVID-19 were analyzed using ANOVA with multiple comparisons (insert statistical package here – I used Prism 9, GraphPad Software, LLC). We examined the relationship between COVID-19 severity and other biomarkers using a Wilcoxon rank sum test for skewed biomarkers (IL-6, LDH, D-dimer, ferritin, and CRP), and a t-test for normally-distributed biomarkers (total fibrinogen). These methods were applied to examine the differences between patients with COVID-19 and controls as well. Prior to running t-tests, an F-test for the equality of variances was run. If unequal variances were found, unequal variance t-tests were run. Otherwise, equal variance t-tests were used.
ROC curves were used to determine the ability of GPF to differentiate between patients with COVID-19 and controls, as well as between patients with severe COVID-19 and mild/moderate COVID-19. Area under the curve (AUC) and 95% confidence intervals (CI) were calculated. For each of these curves, Youden’s index was calculated to determine the GPF cutpoint that maximized sensitivity and specificity. AUC and CI were also calculated for the other biomarkers. Within patients with COVID-19, correlation between GPF and other biomarkers was calculated using Spearman’s rho due to the skewed distribution of most of the biomarkers. All statistical analyses were performed using Stata 16 (StataCorp, College Stations, TX).

**Results**

The general characteristics of the COVID-19 and health control participants are shown in Table 1.

| Variable                          | COVID-19 (N = 103) | Controls (N = 19) |
|-----------------------------------|--------------------|-------------------|
| Age - (years) Mean (SD)           | 49.2 (14.05)       | 37.3 (11.74)      |
| Male- n (%)                       | 59 (57.3)          | 10 (52.6)         |
| Female- n (%)                     | 44 (42.7)          | 9 (47.4)          |
| BMI - (kg/m$^2$) Mean (SD)        | 22.2 (3.87)        | 24.3 (2.85)       |
| Body temperature (°C) - Mean (SD) | 37.6 (0.51)        | 36.6 (0.26)       |
| SpO$_2$ - (%) Median (Q1, Q3)     | 93 (92, 94)        | 98 (96, 99)       |
| Pulse rate - (bpm) Median (Q1, Q3)| 79 (75, 83)        | 72 (70, 73)       |
| Respiratory rate - (breaths per minute) Mean (SD) | 22.7 (1.78) | 20.7 (0.75) |
| Systolic BP - (mm Hg) Mean (SD)   | 123.7 (10.87)      | 119.7 (4.81)      |
| Diastolic BP - (mm Hg) Mean (SD)  | 80.5 (9.52)        | 82.3 (2.69)       |

**Biomarker Comparison between Patients with COVID-19 and Healthy Controls**

The mean GPF in patients with COVID-19 was 69.8 mg/dL, compared to 36.9 mg/dL in controls (mean difference: 32.9 mg/dL [95% CI: 25.6–40.2]; p < 0.0001). We also observed significant differences in median ferritin (p = 0.01) and median D-dimer levels (p = 0.003). Table 2 summarizes the biomarker comparisons by COVID-19 status. Using ROC curves, GPF differentiated between COVID-19 patients and controls very well (AUC 0.91, 95% CI: 0.85–0.98; Youden’s index cutpoint 46.9 mg/dL, sensitivity 0.81, specificity 0.84; Fig. 1A), and all other biomarkers had lower AUC (Fig. 1B).
### Table 2

| Variable                  | COVID-19 (N = 103) | Controls (N = 19) | p-value |
|---------------------------|--------------------|-------------------|---------|
| GPF (mg/dL) - Mean (SD)   | 69.8 (25.66)       | 36.9 (11.47)      | < 0.0001|
| CRP (mg/L) - Median (Q1, Q3) | 14.7 (4.1, 47.3) | 10.1 (5.8, 49.7) | 0.9241  |
| IL-6 (pg/mL) - Median (Q1, Q3) | 10.8 (6.1, 60)  | 6.9 (5.2, 8.1)   | 0.0712  |
| Ferritin (ng/mL) - Median (Q1, Q3) | 139 (66, 402.7) | 71 (49, 133)     | 0.0128  |
| LDH (U/L) - Median (Q1, Q3) | 350.9 (244, 486.5)| 291 (244, 358)   | 0.1458  |
| D-dimer (mg/L) - Median (Q1, Q3) | 0.5 (0.3, 0.96)  | 0.3 (0.2, 0.4)   | 0.0026  |
| Total fibrinogen (mg/dL) - Mean (SD) | 386.0 (128.5) | 357.7 (99.40)     | 0.3661  |

#### Biomarker Comparisons with GPF Levels

Spearman's rho analysis showed that GPF levels in patients with COVID-19 were not significantly correlated with IL-6 (rho = 0.11, p = 0.28), ferritin (rho = 0.04, p = 0.72), D-dimer (rho = 0.18, p = 0.069), or fibrinogen (rho = 0.19, p = 0.051), but were significantly correlated with CRP (rho = 0.23, p = 0.019; rho = 0.23) and LDH (rho = 0.27, p = 0.0064; rho = 0.27), although the rho values do not suggest a robust association.

#### Biomarker Comparison with COVID-19 Disease Severity

GPF was significantly associated with severe (mean = 75.2 mg/dL) vs. mild/moderate (mean = 62.5 mg/dL) COVID-19 severity (mean difference: 12.8 mg/dL [95% CI: 2.8–22.7]; p = 0.012), as defined by SpO₂ levels ≥ 93% (mild/moderate) or < 93% (severe). Pairwise comparisons between the healthy controls and either mild/moderate or severe COVID-19 patients showed significant differences (Fig. 2a). In addition, there was a significant difference in GPF levels between mild/moderate vs. severe COVID-19 patients. In contrast, none of the other biomarkers measured, neither total fibrinogen, CRP, ferritin (Fig. 2a), LDH, D-dimer, nor IL-6 (Fig. 2b) showed significant differences between all three groups. D-dimers did show a significant difference between the healthy controls and the severe COVID-19 patients, but not between the healthy controls and mild/moderate COVID-19 patients nor between mild/moderate vs. severe COVID-19 patients.

Using ROC curves, GPF differentiated between mild/moderate vs. severe COVID-19 patients (AUC 0.68, 95% CI: 0.57–0.78; Youden's index cutpoint of 62.9 mg/dL, sensitivity 0.63, specificity 0.63; Fig. 3A). None of the other biomarkers were significantly associated with severity (p > 0.05; Fig. 3B), and they all had lower AUC.

#### Discussion
We found that GPF levels were increased significantly over controls in hospitalized patients with COVID-19, and had stronger associations with severity of COVID-19 respiratory disease compared to several other inflammatory biomarkers, including CRP, IL-6, ferritin, LDH, D-dimer, and total fibrinogen. Hence these findings have potential clinical implications suggesting that elevated GPF levels may be useful as a biomarker for respiratory disease severity in COVID-19. Furthermore, GPF levels did not significantly correlate with IL-6, ferritin, D-dimer, or total fibrinogen. These findings suggest that the associations between COVID-19 and COVID-19 severity with GPF levels cannot simply be due to total fibrinogen levels.

These findings have potential clinical implications regarding prophylactic anticoagulation of COVID-19 patients. The resistance of GPF-bound thrombin (Fig. 4) to heparin suggests that heparin prophylaxis may be less effective than treatment with other anticoagulants, particularly direct thrombin inhibitors. In point of fact, in critically ill patients with COVID-19, therapeutic-dose heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support\(^9\). It is possible that inhibition of factor Xa by current DOACs may also reduce the levels of active thrombin and thereby prevent activation of thrombin substrates by GPF-bound thrombin, including factor V, factor VIII, factor XI, factor XIII, and fibrinogen, as well as platelet substrates such as PAR-1 and PAR-4. In addition, it is also possible that warfarin anticoagulation may be effective at preventing thrombosis due to GPF-bound thrombin by reducing the levels of active vitamin K-dependent coagulation factors, and therefore, generation of thrombin.

Our study has limitations, in that this was a small observational study without outcome data. It is known that comorbidities including heart disease, hypertension, and diabetes in patients with COVID-19 increase the risk for severe disease and mortality\(^10-13\). These could confound the identified association of COVID-19 severity with levels of GPF. GPF (and indeed the other markers) was measured by a single assay, and thus the findings may not hold true for other assay methods. GPF assays are not available in most labs, unlike the other assays, but a commercial ELISA is now available.

In conclusion, our study suggests that GPF may be a valuable biomarker for assessing COVID-19 respiratory disease severity. Evidence is lacking as to the causal mechanisms or whether the associations are specific to effects of COVID-19 infection or the consequences of a systemic inflammatory response. However, recent \textit{in vitro} evidence demonstrates that high GPF levels in patient plasma increase clot formation at both arterial and venous shear conditions \textit{in vitro}\(^14\). Future investigations of GPF as a driver of thromboinflammation and poor outcomes in COVID-19, and as a biomarker for other inflammatory diseases, both infectious and non-infectious, should be pursued.

\textbf{Declarations}

\textbf{ACKNOWLEDGEMENTS:}

This research is funded by the National Institutes of Health's (NIH) National Institute of General Medical Sciences (NIGMS) under award K23GM130892-01 (L.Z.K.). This study was supported (in part) by
research funding from Gamma Diagnostics, Inc. to J.N. The authors acknowledge resources and support from the Micro Therapeutics Laboratory and Saveetha Medical College, Chennai, India.

AUTHOR CONTRIBUTIONS:

LZK - manuscript preparation

BS - study design, data collection, manuscript preparation

SA - study design, data collection, manuscript preparation

RL - data analysis, manuscript preparation

AJJ - data analysis, manuscript preparation

JN - manuscript preparation

CNR - study design, data collection

JKO - data analysis, manuscript preparation

DHF - study design, manuscript preparation

COMPETING INTERESTS:

OHSU and David H. Farrell have a significant interest in Gamma Diagnostics, a company that may have a commercial interest in the results of this research and technology. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU. Jamie Noll was the Chief Scientific Officer of Gamma Diagnostics, and Lucy Z. Kornblith is a scientific advisor to Gamma Diagnostics. None of the other authors declare any competing interests.

DATA AVAILABILITY:

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

GRANT SUPPORT:

This research is funded by the National Institutes of Health's (NIH) National Institute of General Medical Sciences (NIGMS) under award K23GM130892-01 (L.Z.K.). This study was supported (in part) by research funding from Gamma Diagnostics, Inc. to J.N. The authors acknowledge resources and support from the Micro Therapeutics Laboratory and Saveetha Medical College, Chennai, India.

DATA TRANSPARENCY STATEMENT:

Data, analytical methods and study materials will be made available to other researchers upon request.
STATEMENT ON GUIDELINES:

This study is in compliance with the Declaration of Helsinki statement for the conduct of medical research.

References

1. Gorog, D.A., et al. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat. Rev. Cardiol. 13, 1–21 (2022).

2. Mahat, R.K., Panda, S., Rathore, V., Swain, S., Yadav, L., & Sah, S.P. The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: a systematic review and meta-analysis. Clin. Epidemiol. Glob. Health. 11, 100727 (2021).

3. Gungor, B., et al. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis. Am. J. Emerg. Med. 39, 173–179 (2021).

4. Manolis, A.S., Manolis, T.A., Manolis, A.A., Papatheou, D., & Melita, H. COVID-19 Infection: Viral macro- and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management. J. Cardiovasc. Pharmacol. Ther. 26, 12–24 (2021).

5. Lovely, R.S., et al. γ' fibrinogen: evaluation of a new assay for study of associations with cardiovascular disease. Clin. Chem. 56, 781–788 (2010).

6. Alexander, K.S., Madden, T.E., & Farrell, D.H. Association between γ' fibrinogen levels and inflammation. Thromb. Haemost. 105, 605–609 (2011).

7. Farrell, D.H., et al. Extreme gamma prime fibrinogen levels in COVID-19 patients. Circulation. 144, A9308 (2021).

8. Berlin, D.A., Gulick, R.M., & Martinez, F.J.. Severe Covid-19. N. Engl. J. Med. 383, 2451–2460 (2020).

9. REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N. Engl. J. Med. 385, 777–789 (2021).

10. Zhou, F., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395, 1054–1062 (2020).

11. Corrales-Medina, V.F., et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 125, 773–781 (2012).

12. Udell, J.A., et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 310, 1711–1720 (2013).

13. Bouhanick, B., Cracowski, J-L., Faillie, J-L, & the French Society of Pharmacology, Therapeutics. Diabetes and COVID-19. Therapie. 75, 327–333 (2020).
Figure 1

ROC curve and Youden's index to determine association of COVID-19 with GPF level, and six other biomarkers. A) The AUC for GPF was 0.91 (95% CI: 0.85-0.98). Youden's index cutpoint was 46.9 mg/dL between healthy controls and patients with COVID-19. The sensitivity at this cutpoint was 0.81 and the specificity was 0.84. B) The AUC for CRP was 0.51 (95% CI: 0.37-0.64). The AUC for IL-6 was 0.63 (95% CI: 0.51-0.75). The AUC for ferritin was 0.68 (95% CI: 0.56-0.80). The AUC for LDH was 0.61 (95% CI: 0.49-0.72). The AUC for D-dimer was 0.72 (95% CI: 0.62-0.81). The AUC for total fibrinogen was 0.55 (95% CI: 0.41-0.70).
Pairwise comparisons between biomarkers in healthy controls, mild/moderate COVID-19 patients, and severe COVID-19 patients. We examined the relationship between COVID-19 severity and other biomarkers using a Wilcoxon rank sum test for skewed biomarkers (GPF, IL-6, LDH, D-dimer, ferritin, and CRP), and a t-test for normally-distributed biomarkers (total fibrinogen).
Figure 3

Relationship between COVID-19 severity, GPF level, and six other biomarkers. COVID-19 severity was determined by SpO$_2$ levels, with mild/moderate defined as SpO$_2$ >93%, and severe as SpO$_2$ ≤ 93%. A) The AUC for GPF was 0.68 (95% CI: 0.57-0.78). Youden's index cutpoint was 62.9 mg/dL between mild/moderate vs. severe COVID-19. The sensitivity at this cutpoint was 0.64 and the specificity was 0.63. B) The AUC for CRP was 0.56 (95% CI: 0.44-0.67). The AUC for IL-6 was 0.54 (95% CI: 0.43-0.66). The AUC for ferritin was 0.42 (95% CI: 0.31-0.53). The AUC for LDH was 0.60 (95% CI: 0.49-0.71). The AUC for D-dimer was 0.58 (95% CI: 0.47-0.70). The AUC for total fibrinogen was 0.56 (95% CI: 0.45-0.68).
Figure 4

Model of GPF mechanism of thrombosis. The model starts with free thrombin cleaving fibrinopeptides A and B from all forms of fibrinogen via its active site (cutout triangle). This converts the fibrinogen to fibrin, which polymerizes into an insoluble clot. The free thrombin can then bind to GPF via thrombin anion-binding exosite II (cutout square), concentrating active thrombin on the growing fibrin clot. This
bound thrombin is resistant to heparin, since heparin binds to anion-binding exosite II, which is blocked by the g' chain.